Alzheimer's disease and other dementias: Advances in 2014

The Lancet Neurology

Volumn 14, Issue 1, 2015, Pages 4-6

  Bateman, Randall ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; DEMENTIA; HUMAN;

ALZHEIMER DISEASE; DEMENTIA; HUMANS;

EID: 84918582408     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70301-1     Document Type: Note

References (17)

1. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
2. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:311-321. for the Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study GroupSolanezumab Study Group.
3. Cummings J, Cho W, Ward M, et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. Alzheimer's Association International Conference; Copenhagen, Denmark, July 11-17, 2014.
4. Forman M, Kleijn H-J, Dockendorf M, et al. The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimers Dement 2013, 9:P139.
5. Alexander R, Budd Haeberlein S, Rosen L, et al. AZD3293 a novel BACE1 inhibitor: pharmacokinetics and effects on plasma and CSF Aβ peptides following multiple-dose administration in Alzheimer's disease patients. Clinical Trials in Alzheimer's Disease Conference; Philadelphia, PA, USA Nov 20-22, 2014. P1-30.
6. Ayutyanont N, Langbaum JBS, Hendrix SB, et al. The Alzheimer's Prevention Initiative Composite Cognitive Test Score: Sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry 2014, 75:652-660.
7. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med 2014, 6:228fs13.
8. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol 2013, 169:737-743.
9. Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using F-18-THK5105 PET. Brain 2014, 137:1762-1771.
10. Shah M, Catafau AM Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers. J Nucl Med 2014, 55:871-874.
11. Sepulcre J, Johnson KA, Sperling R Tau and AB deposits relate to distinctive functional connectivity disruptions in the elderly brain. Alzheimers Dement 2014, 10:P159-P160.
12. Tran HT, Chung CH, Iba M, et al. Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 2014, 7:2054-2065.
13. Holmes BB, Furman JL, Mahan TE, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sic USA 2014, 111:E4376-E4385.
14. Choi SH, Kim YH, Hebisch M, et al. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 2014, 515:274-278.
15. Villeda SA, Plambeck KE, Middeldorp J, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 2014, 20:659-663.
16. Cruchaga C, Karch CM, Jin SC, et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 2014, 505:550-554.
17. Cady J, Koval ED, Benitez BA, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 2014, 71:449-453.